All In Biotech

Drug Trial Radar · NCT07459543

A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India

A Phase 4, Single Arm, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in Participants With Unresectable or Metastatic Melanoma in India.

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 15, 2026

Primary completion

May 26, 2029

Study completion May 28, 2029

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in unresectable or metastatic melanoma participants in India.

Conditions

  • Unresectable Melanoma
  • Metastatic Melanoma

Interventions

  • Nivolumab + RelatlimabDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: Up to 30 weeks
  2. Incidence of drug-related AEsTime frame: Up to 30 weeks
  3. Incidence of serious adverse events (SAEs)Time frame: Up to 30 weeks
  4. Incidence of drug-related SAEsTime frame: Up to 30 weeks
  5. Incidence of immune-mediated adverse events (IMAEs)Time frame: Up to 30 weeks
  6. AEs leading to discontinuation of treatmentTime frame: Up to 30 weeks
  7. Number of deathsTime frame: Up to 30 weeks
  8. Number of participants with laboratory abnormalitiesTime frame: Up to 30 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0011

    Bhubaneswar, India

  • Local Institution - 0002

    Chennai, India

  • Local Institution - 0006

    Mumbai, India

  • Local Institution - 0005

    Nagpur, India

  • Local Institution - 0004

    New Delhi, India

  • Local Institution - 0001

    New Delhi, India

  • Local Institution - 0012

    Nashik, Dādra and Nagar Haveli and Damān and Diu, India

  • Local Institution - 0010

    Mumbai, Maharashtra, India

  • Local Institution - 0009

    Navi Mumbai, Maharashtra, India

  • Local Institution - 0008

    Pune, Maharashtra, India

  • Local Institution - 0003

    Bhubaneswar, Odisha, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.